MKI67 and cervical cancer: An integral assessment of the expression profile of MKI67, PGR, CDKN2A, and BCL2 identified 45 patients (41%) at risk for developing cervical cancer: 14 (47%) from the LSIL group, 9 (30%) from the HSIL group, 22 (73%) patients from the cervical cancer group, and none of the patients from the group with cervicitis.